New Agreement with Global Pharma Company

RNS Number : 4592Y

Physiomics PLC

01 March 2012

 



Physiomics plc

("Physiomics") or ("the Company")

New Agreement to advance oncology candidate with global pharma company

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a new agreement with a major global pharmaceutical company.  Under the agreement, Physiomics will determine the optimal dosing and timing of a new compound currently under development by this new client, in combination with irradiation therapy. 

The project will be performed on a fee-for-service basis.

Dr Mark Chadwick, CEO of Physiomics, commented:

"We are very excited to have added a second major pharmaceutical company to our customer list. This new relationship is a vindication of our strategy of approaching the larger pharmaceutical companies who can benefit most from our technology. We anticipate that this will lead to further business from this sector."

Enquiries:

Physiomics plc                                                  

Dr Mark Chadwick, CEO

[phone]

WH Ireland Limited (broker/nomad)

Katy Mitchell

[phone]

Media enquiries:

The Communications Portfolio Ltd

Ariane Comstive / Caolan Mahon [phone] / 2029

[e-mail]

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million¹.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

¹Tufts Centre Impact Report 2002

 

END

 

 

AGRLIFLDVAILIIF